DENOSUMAB (Jubereq®)

Clinical Indication

Prevention of skeletal related events in adults with bone metastases from solid tumours other than prostate

Comments

Full SCA

Biosimilar of denosumab; preferred first-line option in LLR for prevention of skeletal related events in adults with bone metastases from solid tumours other than prostate (120mg vial).

Date of classification

February 2026

Orange

Shared Care Agreement. Higher risk medicines requiring significant regular monitoring which would be initiated by or at the recommendation of a specialist service which may include mental health services, secondary care, tertiary care, community providers, private providers and GPs with a specialist interest.